Actelion confirms $2.5B offer for ZS Pharma

Actelion is often thrown around as a possible buyout target--most recently, for deal-hungry Shire. But the Swiss biotech has its sights set on a pickup of its own. It's discussing a $2.5 billion buyout of ZS Pharma, it confirmed Thursday, sending shares of its target soaring. More from FierceBiotech

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."